Electronic Supplementary Information

Aryne [3+2] Cycloaddition with *N*-Sulfonylpyridinium Imides and *in situ* Generated *N*-Sulfonylisoquinolinium Imides: A Potential Route to Pyrido[1,2-*b*]indazoles and Indazolo[3,2-*a*]isoquinolines

Jingjing Zhao,^a Pan Li,^a Chunrui Wu,^{*a} Hongli Chen,^a Wenying Ai,^a Renhong Sun,^a Hailong Ren,^a Richard C. Larock,^b and Feng Shi^{*a}

^aKey Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Jinming Campus, Kaifeng, Henan 475004, China PR. Fax: +(86)-378-2864665; Tel: +(86)-378-2864665;

^b Department of Chemistry, Iowa State University, Ames, IA 50010, U.S.A.

E-mail: cwu@henu.edu.cn, fshi@henu.edu.cn.

Table of Contents

General Information	ESI2
Preparation of the <i>N</i> -Sulfonylpyridinium Imides	ESI2-ESI4
Preparation of the N'-(2-Alkynylbenzylidene)tosylhydrazides	ESI5-ESI6
Reaction Procedures and Characterization of the Products	ESI7-ESI17
References and Notes	ESI18
Copies of ¹ H and ¹³ C NMR Spectra, including 2D NMR Spectra	ESI19-ESI120

General Information:

All reagents purchased from commercial sources were used as received.¹ The solvents THF and MeCN were distilled from Na/benzophenone and CaH₂, respectively. The silica gel for column chromatography was supplied as 300-400 mesh from Haiyang Chemicals (Qingdao, China).² Powered CsF was used as received and stored in a desiccator.

All melting points were measured on an X-6 microscopic melting point apparatus and are uncorrected. The ¹H and ¹³C NMR spectra were recorded on a Bruker AVANCE spectrometer and are referenced to the residual solvent signals (7.26 ppm for ¹H and 77.0 ppm for ¹³C in CDCl₃, 25.3 ppm for ¹³C in THF- d_8). The HRMS spectra were recorded on a Bruker APEX IV spectrometer.

All aryne cycloaddition reactions were carried out in oven-dried glassware and were magnetically stirred. Microwave reactions were carried out on a CEM Discovery microwave reactor.

Preparation of the *N*-Sulfonylpyridinium Imides:³



To a mixture of H₂O and THF (0.5 mL each) was added pyridine (0.100 mL, 1.24 mmol), followed by *O*-(2,4-Dinitrophenyl)hydroxylamine (272 mg, 1.36 mmol). The reaction flask was sealed, and the resultant suspension was stirred at 40 °C for 12 h, during which time the reaction mixture turned dark-red. Upon completion, the reaction mixture was cooled to room temperature and was sequentially treated with an NaOH solution (2.5 *N*, 6 mL), followed by a *p*-toluenesulfonyl chloride solution (355 mg, 1.86 mmol, in 2 mL of THF) dropwise. After another 4 h, the reaction was diluted with H₂O and extracted three times with CH₂Cl₂. The combined organic phases were washed once with 2.5 *N* NaOH, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (CH₂Cl₂/MeOH 9:1) to afford **7a** as a yellow solid (281 mg, 91%), mp 213 °C (lit⁴ 215 °C); ¹H NMR (300 MHz, CDCl₃) δ 8.47 (d, *J* = 1.4 Hz, 1 H), 8.44 (d, *J* = 1.2 Hz, 1 H), 7.99 (t, *J* = 7.8 Hz, 1 H), 7.64-7.57 (m, 4 H), 7.16 (d, *J* = 8.0 Hz, 2 H), 2.35 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 145.2, 141.6, 138.6, 138.5, 129.2, 127.0, 126.7, 21.4.

Following the above procedure, all *N*-sulfonylpyridinium imides were prepared. Compounds **7a-7g**, **7k-7n**, **11a** and **13a** have been reported before in our earlier communication.⁵ Other compounds are listed in Table ESI1:

Table ESI1. Preparation and characterization of N-sulfonylpyridinium imides



entry	compound 7/16	yield (%)	mp (⁰C)	characterization		
1	7h R ¹ = 2,6-Me ₂ R = Ts	85	167-168	¹ H NMR (400 MHz, CDCl ₃) δ 7.70 (t, <i>J</i> = 7.8 Hz, 1 H), 7.66 (d, <i>J</i> = 8.2 Hz, 2 H), 7.37 (d, <i>J</i> = 7.8 Hz, 2 H), 7.19 (d, <i>J</i> = 7.9 Hz, 2 H), 2.58 (s, 6 H), 2.38 (s, 3 H); ¹³ C NMR (75 MHz, CDCl ₃) δ 159.2, 142.9, 140.9, 137.7, 129.2, 126.0, 125.7, 21.34, 21.26; HRMS (ESI) calcd for C ₁₄ H ₁₇ N ₂ O ₂ S (M+H) 277.1005, found 277.1000.		
2	7i R ¹ = 2,4-Me ₂ R = Ts	33	238-239	¹ H NMR (300 MHz, CDCl ₃) δ 8.38 (d, $J = 6.6$ Hz, 1 H), 7.60-7.55 (m, 2 H), 7.25 (s, 1 H), 7.22-7.18 (m, 1 H), 7.16 (d, $J = 8.0$ Hz, 2 H), 2.47 (s, 3 H), 2.39 (s, 3 H), 2.36 (s, 3 H); ¹³ C NMR (100 MHz, DMSO- <i>d</i> ₆) δ 154.3, 152.1, 145.6, 141.3, 140.6, 129.3, 128.6, 126.0, 125.4, 20.9, 20.6, 18.8; HRMS (ESI) calcd for C ₁₄ H ₁₇ N ₂ O ₂ S (M+H) 277.1005, found 277.1005.		
3	7j R ¹ = 2,3,5-Me ₃ R = Ts	26	150	¹ H NMR (300 MHz, CDCl ₃) δ 8.18 (s, 1 H), 7.61-7.53 (m, 2 H), 7.50 (s, 1 H), 7.16 (d, J = 7.9 Hz, 2 H), 2.37 (s, 6 H), 2.32 (s, 3 H), 2.28 (s, 3 H); ¹³ C NMR (100 MHz, DMSO- <i>d</i> ₆) δ 151.9, 143.6, 141.1, 141.0, 140.6, 136.2, 133.3, 129.2, 126.0, 20.9, 19.1, 17.1, 15.2; HRMS (ESI) calcd for C ₁₅ H ₁₉ N ₂ O ₂ S (M+H) 291.1162, found 291.1162.		
4	7o R ¹ = 3-morpholino R = Ts	60	193-194	¹ H NMR (400 MHz, CDCl ₃) δ 8.01 (s, 1 H), 7.76-7.72 (m, 1 H), 7.63 (d, $J = 8.2$ Hz, 2 H), 7.34-7.30 (m, 2 H), 7.17 (d, $J = 8.0$ Hz, 2 H), 3.84 (t, $J = 4.9$ Hz, 4 H), 3.17 (t, $J = 5.0$ Hz, 4 H), 2.36 (s, 3 H); HRMS (ESI) calcd for C ₁₆ H ₂₀ N ₃ O ₃ S (M+H) 334.1220, found 334.1221.		
5	7p R ¹ = 3-Br-5-OMe R = Ts	74	199-200	¹ H NMR (400 MHz, CDCl ₃) δ 8.21 (t, <i>J</i> = 1.4 Hz, 1 H), 8.17 (dd, <i>J</i> = 2.2, 1.4 Hz, 1 H), 7.68 (d, <i>J</i> = 8.2 Hz, 2 H), 7.53 (dd, <i>J</i> = 2.2, 1.6 Hz, 1 H), 7.21 (d, <i>J</i> = 8.0 Hz, 2 H), 3.86 (s, 3 H), 2.38 (s, 3 H); ¹³ C NMR (100 MHz, DMSO- <i>d</i> ₆) δ 157.5, 141.3, 138.7, 137.5, 132.4, 129.3, 127.4, 126.8, 120.7, 57.5, 20.9; HRMS (ESI) calcd for C ₁₃ H ₁₄ BrN ₂ O ₃ S (M+H) 356.9903, found 356.9906.		
6	16a R ¹ = 2,6-Me ₂ R = Ns	48	191-192	¹ H NMR (400 MHz, CDCl ₃) δ 8.15 (d, <i>J</i> = 7.8 Hz, 1 H), 7.79 (t, <i>J</i> = 7.8 Hz, 1 H), 7.62 (t, <i>J</i> = 7.6 Hz, 1 H), 7.54 (t, <i>J</i> = 7.6 Hz, 1 H), 7.47 (d, <i>J</i> = 7.8 Hz, 1 H), 7.43 (d, <i>J</i> = 7.8 Hz, 2 H), 2.65 (s, 6 H); ¹³ C NMR (100 MHz, DMSO- <i>d</i> ₆) δ 157.6, 147.2, 139.5, 138.2, 132.3, 132.1, 129.0, 126.4, 123.4, 20.4; HRMS (ESI) calcd for C ₁₃ H ₁₄ N ₃ O ₄ S (M+H) 308.0700, found 308.0696.		

				^{1}H NMR (400 MHz, CDCl_3) δ 8.24 (s, 1 H), 8.20-8.17 (m, 2 H), 7.70
7	16b R ¹ = 3-Br-5-OMe	46	154-155	(m, 1 H), 7.65 (t, J = 7.6 Hz, 1 H), 7.57 (t, J = 7.6 Hz, 1 H), 7.45 (d,
				\textit{J} = 7.8 Hz, 1 H), 3.94 (s, 3 H); ^{13}C NMR (100 MHz, DMSO- \textit{d}_6) δ
				157.8, 148.0, 138.5, 133.9, 133.4, 132.8, 132.0, 130.2, 128.6,
	R = INS			123.2, 121.0, 57.7; HRMS (ESI) calcd for $C_{12}H_{11}BrN_3O_5S$ (M+H)
				387.9597, found 387.9597.
		42	189-190	¹ H NMR (300 MHz, CDCl ₃) δ 8.63 (s, 1 H), 8.53 (d, J = 6.3 Hz, 1 H),
	16.			8.22-8.18 (m, 2 H), 7.65 (dt, J = 1.0, 8.9 Hz, 1 H), 7.60-7.54 (m, 2
o	$P^1 = 2 Pr$			H), 7.44 (d, J = 7.8 Hz, 1 H); ¹³ C NMR (100 MHz, DMSO- d_6) δ
8	R = 3-DI			147.9, 146.4, 144.7, 143.7, 134.1, 132.8, 132.0, 130.1, 128.4,
	R = NS			123.2, 121.0; HRMS (ESI) calcd for $C_{11}H_9N_3O_4S$ (M+H) 357.9492,
				found 357.9494.
		35	137-138	¹ H NMR (400 MHz, CDCl ₃) δ 9.00 (dd, J = 1.5, 1.1 Hz, 1 H), 8.70
	16d R ¹ = 3-CO ₂ Me R = Ns			(dt, J = 6.3, 1.4 Hz, 1 H), 8.65 (dt, J = 8.1, 1.4 Hz, 1 H), 8.20 (dd, J
				= 7.9, 1.4 Hz, 1 H), 7.80 (ddd, J = 8.0, 6.3, 0.4 Hz, 1 H), 7.65 (td, J
q				= 7.7, 1.3 Hz, 1 H), 7.55 (td, <i>J</i> = 7.7, 1.4 Hz, 1 H), 7.41 (dd, <i>J</i> = 7.9,
0				1.2 Hz, 1 H), 3.99 (s, 3 H); ^{13}C NMR (75 MHz, CDCl_3) δ 161.8,
				148.5, 147.9, 146.1, 140.0, 135.5, 132.1, 131.8, 130.6, 130.0,
				127.1, 123.0, 53.5; HRMS (ESI) calcd for $C_{13}H_{12}N_3O_6S$ (M+H)
				338.0441, found 338.0440.
		54	205-206	¹ H NMR (300 MHz, CDCl ₃) δ 8.16 (dd, <i>J</i> = 7.9, 1.4 Hz, 1 H), 8.11
	16e			(s, 2 H), 7.67 (s, 1 H), 7.61 (td, <i>J</i> = 7.7, 1.4 Hz, 1 H), 7.53 (td, <i>J</i> =
10	$R^1 = 3.5$ -Me ₂ R = Ns			7.6, 1.5 Hz, 1 H), 7.41 (dd, <i>J</i> = 7.8, 1.3 Hz, 1 H), 2.40 (s, 6 H); ¹³ C
10				NMR (100 MHz, DMSO-d ₆) δ 147.9, 142.3 (two carbons), 137.4,
				134.5, 132.5, 131.6, 130.0, 123.2, 17.5; HRMS (ESI) calcd for
				$C_{13}H_{14}N_3O_4S$ (M+H) 308.0700, found 308.0697.

Preparation of the N'-(2-Alkynylbenzylidene)tosylhydrazides:



To an oven-dried 10 mL microwave-adaptive vial equipped with a stir bar was charged with 925 mg of 2-bromobenzaldehyde (5 mmol), followed by 696 mg of 4-ethynyltoluene (6 mmol, 1.2 equiv). Et₃N (1 mL) and DMF (4 mL) were added, followed by $PdCl_2(PPh_3)_2$ (70 mg, 0.1 mmol, 2 mol %) and Cul (38 mg, 0.2 mmol, 4 mol %). The vial was sealed and irradiated with microwave at 100 °C for 2 h. The mixture was cooled to room temperature, poured into 50 mL of EtOAc, and washed three times with brine. The organic layer was dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (15:1 petroleum ether/EtOAc) to afford 850 mg of 2-(*p*-tolylethynyl)benzaldehyde (77% yield) as a brown solid.⁶

To an oven-dried 25 mL round-bottom flask containing 409 mg of *p*-toluenesulfonyl hydrazide (2.2 mmol, 1.1 equiv) and 5 mL of absolute MeOH was added 2-(*p*-tolylethynyl)benzaldehyde (2 mmol) obtained from the above step. The mixture was stirred at room temperature for 2 h and the volatiles were evaporated *in vacuo*. The residue was recrystallized from minimum amount of MeOH to afford 640 mg of *N*'-(2-alkynylbenzylidene)tosylhydrazides (82% yield) as white crystals.⁷

Following the above procedure, the following *N'*-(2-alkynylbenzylidene)tosylhydrazides were prepared (Table ESI2):

	R ²			
CUO	PdCl ₂ (PPh ₃) ₂ (2 mol %)	СНО		
	Cul (4 mol %)	R ¹	TsNHNH ₂	R ¹ N Ts
	Et ₃ N/DMF 1:4		MeOH, rt, 2 h	
	MW, 100 °C, 2 h	R^2		R ²

Table ESI2. Preparation and characterization	of N'-(2-alkynylbenzylidene)tosylhydrazides
--	---

entry	compound 3 (R ¹ , R ²)	yield (%) (step 1)	yield (%) (step 2)	mp (ºC)	¹ H NMR (300 MHz, CDCl ₃)
1	3a R ¹ = H R ² = 4-MeC ₆ H ₄	77	82	159-161	8.35 (s, 1 H), 7.97 (s, 1 H), 7.95-7.93 (m, 1 H), 7.89 (d, $J = 8.3$ Hz, 2 H), 7.52-7.46 (m, 1 H), 7.41 (d, $J = 8.1$ Hz, 2 H), 7.35-7.30 (m, 4 H), 7.17 (d, $J = 7.9$ Hz, 2 H), 2.40 (s, 3 H), 2.38 (s, 3 H) ^a
2	3b R ¹ = 4-F R ² = Ph	80	67	155-156	8.31 (s, 1 H), 8.15 (s, 1 H), 7.95-7.90 (m, 1 H), 7.89-7.87 (m, 2 H), 7.53-7.50 (m, 2 H), 7.39-7.34 (m, 3 H), 7.31 (d, <i>J</i> = 8.1 Hz, 2 H), 7.18 (dd, <i>J</i> = 9.0, 2.6 Hz, 1 H), 7.03 (td, <i>J</i> = 8.4, 2.6 Hz, 1 H), 2.41 (s, 3 H)
3	3c R ¹ = 4-Me R ² = Ph	70	72	161-162	8.32 (s, 1 H), 7.89-7.87 (m, 2 H), 7.86-7.81 (m, 2 H), 7.53-7.50 (m, 2 H), 7.39-7.34 (m, 3 H), 7.32 (s, 1 H), 7.30 (d, <i>J</i> = 8.0 Hz, 2 H), 7.14 (d, <i>J</i> = 8.1 Hz, 1 H), 2.40 (s, 3 H), 2.35 (s, 3 H)

4	3d R ¹ = 5-Cl R ² = Ph	78	63	163-165	8.28 (s, 1 H), 8.05 (s, 1 H), 7.91-7.87 (m, 3 H), 7.54-7.48 (m, 2 H), 7.43 (d, <i>J</i> = 8.3 Hz, 1 H), 7.38-7.36 (m, 2 H), 7.34-7.31 (m, 3 H), 7.28 (dd,
5	3e R ¹ = 5-OMe R ² = Ph	62	86	148-149	J = 9.2, 2.2 Hz, 1 H), 2.42 (s, 3 H) 8.32 (s, 1 H), 7.93 (s, 1 H), 7.88 (d, $J = 8.3 \text{ Hz}, 2$ H), 7.53-7.47 (m, 2 H), 7.44 (s, 1 H), 7.42 (d, $J =$ 5.6 Hz, 1 H), 7.37-7.29 (m, 5 H), 6.91 (dd, $J =$ 8.6 Hz, 1 H), 3.86 (s, 3 H), 2.40 (s, 3 H)
6	3f R ¹ = H R ² = Ph	72	62	152-153 (lit ⁸ 158-161)	8.36 (s, 1 H), 8.07 (s, 1 H), 7.97-7.92 (m, 1 H), 7.92-7.85 (m, 2 H), 7.56-7.47 (m, 3 H), 7.39-7.27 (m, 7 H), 2.40 (s, 3 H)
7	3g R ¹ = H R ² = 3-CIC ₆ H ₄	74	70	152-153	8.30 (s, 1 H), 7.96-7.93 (m, 1 H), 7.89-7.86 (m, 2 H), 7.51-7.48 (m, 2 H), 7.40-7.37 (m, 1 H), 7.36-7.27 (m, 7 H), 2.40 (s, 3 H)
8	3h $R^1 = H$ $R^2 = 3-(MeO)C_6H_4$	68	74	147-148	8.35 (s, 1 H), 8.03 (s, 1 H), 7.98-7.92 (m, 1 H), 7.89-7.87 (m, 2 H), 7.54-7.47 (m, 1 H), 7.38-7.22 (m, 5 H), 7.11 (dt, <i>J</i> = 7.6, 1.2 Hz, 1 H), 7.04 (dd, <i>J</i> = 2.5, 1.4 Hz, 1 H), 6.92 (ddd, <i>J</i> = 8.3, 2.6, 0.9 Hz, 1 H), 3.83 (s, 3 H), 2.40 (s, 3 H)
9	3i R ¹ = H R ² = 3-thiophenyl	54	54	139-140	8.33 (s, 1 H), 7.96–7.91 (m, 2 H), 7.88 (d, <i>J</i> = 8.3 Hz, 2 H), 7.55 (dd, <i>J</i> = 2.9, 1.0 Hz, 1 H), 7.51–7.45 (m, 1 H), 7.35–7.28 (m, 5 H), 7.19 (dd, <i>J</i> = 5.0, 0.9 Hz, 1 H), 2.41 (s, 3 H)
10	3j R ¹ = H R ² = 2-pyridyl	58	78	128-130	10.49 (s, 1 H), 8.66 (ddd, <i>J</i> = 4.9, 1.7, 0.9 Hz, 1 H), 8.42 (s, 1 H), 7.89 (d, <i>J</i> = 8.3 Hz, 2 H), 7.77 (d, <i>J</i> = 7.2 Hz, 1 H), 7.58 (dt, <i>J</i> = 7.7, 1.8 Hz, 1 H), 7.33-7.27 (m, 3 H), 7.21 (d, <i>J</i> = 7.8 Hz, 1 H), 7.14 (t, <i>J</i> = 7.3 Hz, 1 H), 7.03 (td, <i>J</i> = 7.6, 1.3 Hz, 1 H), 6.77 (d, <i>J</i> = 7.6 Hz, 1 H), 2.38 (s, 3 H)
11	3k R ¹ = H R ² = pentyl	55	36	117-118	8.24 (s, 1 H), 7.89-7.87 (m, 3 H), 7.81 (s, 1 H), 7.38-7.26 (m, 5 H), 2.44-2.39 (m, 2 H), 2.41 (s, 3 H), 1.68-1.53 (m, 2 H), 1.46-1.30 (m, 4 H), 0.92 (t, <i>J</i> = 6.9 Hz, 3 H)
12	3I $R^1 = H$ $R^2 = (CH_2)_2OTHP$	26	72	116-117	8.60 (s, 1 H), 8.37 (s, 1 H), 7.95-7.81 (m, 3 H), 7.35-7.23 (m, 5 H), 4.70 (dd, <i>J</i> = 4.9, 2.7 Hz, 1 H), 4.09-3.99 (m, 1 H), 3.93 (ddd, <i>J</i> = 9.5, 7.8, 5.6 Hz, 1 H), 3.70 (dt, <i>J</i> = 9.6, 5.7 Hz, 1 H), 3.61-3.49 (m, 1 H), 2.86-2.60 (m, 2 H), 2.40 (s, 3 H), 1.90-1.49 (m, 6 H)
13	3m R ¹ = H R ² = TMS	84	87	149-150	8.24 (s, 1 H), 7.97 (s, 1 H), 7.93-7.85 (m, 3 H), 7.46-7.40 (m, 1 H), 7.36-7.27 (m, 4 H), 2.41 (s, 3 H), 0.25 (s, 9 H)

^a 400 MHz spectrum.

Reaction Procedures and Characterization of the Products:

Pyrido[1,2-b]indazoles and Analogues:5

General procedure: To a 10 mL round-bottom flask equipped with a stirr bar was added *N*-sulfonylpyridinium imide **7** (0.3 mmol), followed by aryne precursor **10** (0.36 mmol). THF (4 mL) was added and the mixture was briefly stirred before addition of CsF (ca. 0.9 mmol). The flask was fitted with a refluxing condenser and sealed with a septum. A balloon was added on top, and the mixture was stirred in a 70 °C oil bath for 24 h. Upon judged completion by TLC, the mixture was diluted with EtOAc and water. Layers were separated and the aqueous layer was extracted with EtOAc twice. The combined organic phases were dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the desired product.



Pyrido[1,2-*b***]indazole (8a**): yield 43 mg (85%); light yellow solid; mp 85 °C (lit⁹ 83-84 °C); ¹H NMR (300 MHz, CDCl₃) δ 8.80 (dt, J = 6.9, 1.0 Hz, 1 H), 8.17-8.06 (m, 2 H), 7.85 (dt, J = 8.7, 0.8 Hz, 1 H), 7.62-7.53 (m, 1 H), 7.41-7.32 (m, 1 H), 7.25-7.15 (m, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ 149.6, 135.4, 128.4, 127.9, 121.9, 119.8, 119.7, 117.9, 116.2, 115.5, 115.2; IR (KBr) 1644, 1604, 1510, 1430, 1360, 1213, 1141, 741, 718 cm⁻¹; HRMS (ESI) calcd for C₁₁H₉N₂ (M+H) 169.0760, found 169.0760.



2,3-Dimethoxypyrido[1,2-*b***]indazole (8b**): yield 60 mg (88%); white solid; mp 132 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, *J* = 7.0 Hz, 1 H), 7.94 (d, *J* = 8.7 Hz, 1 H), 7.31 (s, 1 H), 7.27-7.22 (m, 1 H), 7.16 (s, 1 H), 7.02 (td, *J* = 6.9, 1.2 Hz, 1 H), 4.02 (s, 3 H), 4.01 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 152.4, 146.0, 134.7, 127.70, 127.67, 121.1, 116.9, 114.0, 108.0, 98.0, 94.8, 56.0, 55.8; HRMS (ESI) calcd for C₁₃H₁₃N₂O₂ (M+H) 229.0972, found 229.0968.



1-Methoxypyrido[**1**,**2**-*b*]**indazole** (**8c**): yield 46 mg (77%); off-white solid; mp 100 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.76 (dt, *J* = 6.9, 0.9 Hz, 1 H), 8.34 (dt, *J* = 8.4, 1.3 Hz, 1 H), 7.48 (dd, *J* = 8.6, 7.3 Hz, 1 H), 7.43-7.33 (m, 2 H), 7.16 (td, *J* = 6.9, 1.5 Hz, 1 H), 6.53 (d, *J* = 7.3 Hz, 1 H), 4.08 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 151.2, 135.1, 129.2, 127.5, 122.3, 120.1, 115.6, 107.8, 107.0, 97.8, 55.4; HRMS (ESI) calcd for C₁₂H₁₁N₂O (M+H) 199.0866, found 199.0861.



Benzo[e]pyrido[1,2-b]indazole (8d) and Benzo[g]pyrido[1,2-b]indazole (8d'): due to the limited

quantity of the two regioisomers separated and poor regioselectivity, we did not attempt to assign the regioisomers. Isomer A: beige solid; mp 140-141 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.86 (d, *J* = 7.0 Hz, 1 H), 8.81-8.72 (m, 1 H), 8.08 (d, *J* = 8.7 Hz, 1 H), 8.01-7.90 (m, 2 H), 7.70-7.60 (m, 2 H), 7.53 (d, *J* = 8.8 Hz, 1 H), 7.43-7.32 (m, 1 H), 7.12 (td, *J* = 6.9, 1.3 Hz, 1 H); HRMS (ESI) calcd for C₁₅H₁₁N₂ (M+H) 219.0917, found 219.0916. Isomer B: beige solid; mp 145 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.85 (d, *J* = 7.0 Hz, 1 H), 8.47 (t, *J* = 8.1 Hz, 2 H), 7.97 (d, *J* = 8.0 Hz, 1 H), 7.90-7.82 (m, 2 H), 7.74-7.66 (m, 1 H), 7.54-7.44 (m, 2 H), 7.15 (td, *J* = 6.9, 1.2 Hz, 1 H); HRMS (ESI) calcd for C₁₅H₁₁N₂ (M+H) 219.0917, found 219.0916.



7-Methylpyrido[1,2-*b*]indazole (8e): yield 51 mg (93%); beige solid; mp 70 °C (lit¹⁰ 63-64 °C); ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.2 Hz, 1 H), 8.07 (d, *J* = 8.6 Hz, 1 H), 7.93 (d, *J* = 8.4 Hz, 1 H), 7.58 (t, *J* = 7.6 Hz, 1 H), 7.35 (t, *J* = 7.6 Hz, 1 H), 7.23 (t, *J* = 7.5 Hz, 1 H), 7.10 (d, *J* = 7.0 Hz, 1 H), 2.96 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.4, 137.6, 135.7, 128.3, 121.9, 119.9, 119.5, 115.73, 115.67, 115.6, 115.4, 18.6; HRMS (ESI) calcd for C₁₂H₁₁N₂ (M+H) 183.0917, found 183.0912.



9-Methylpyrido[1,2-*b*]indazole (8f): yield 49 mg (90%); beige solid; mp 133 °C (lit¹⁰ 116-121 °C); ¹H NMR (300 MHz, CDCl₃) δ 8.68 (d, *J* = 7.1 Hz, 1 H), 8.04 (dt, *J* = 8.2, 1.0 Hz, 1 H), 7.90 (dt, *J* = 1.8, 0.9 Hz, 1 H), 7.79 (d, *J* = 8.7 Hz, 1 H), 7.54 (ddd, *J* = 8.6, 6.7, 1.1 Hz, 1 H), 7.18 (ddd, *J* = 8.1, 6.8, 0.8 Hz, 1 H), 7.02 (dd, *J* = 7.1, 1.9 Hz, 1 H), 2.55 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 150.0, 135.4, 133.0, 128.3, 127.2, 119.8, 119.1, 118.5, 116.8, 115.3, 114.5, 21.2; IR (KBr) 1648, 1608, 1356, 804, 747 cm⁻¹; HRMS (ESI) calcd for C₁₂H₁₁N₂ (M+H) 183.0917, found 183.0912.



Ethyl pyrido[1,2-*b*]indazole-9-carboxylate (8g): yield 65 mg (90%); slightly yellow solid; mp 98 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.86 – 8.82 (m, 1 H), 8.76 (d, J = 7.2 Hz, 1 H), 8.16 (dd, J = 8.3, 0.9 Hz, 1 H), 7.91 (dd, J = 8.7, 0.7 Hz, 1 H), 7.77 (dd, J = 7.2, 1.9 Hz, 1 H), 7.66-7.58 (m, 1 H), 7.38-7.30 (m, 1 H), 4.46 (q, J = 7.1 Hz, 2 H), 1.46 (t, J = 7.1 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 164.9, 150.1, 134.3, 128.8, 127.3, 123.3, 121.4, 120.1, 119.7, 116.9, 116.4, 115.5, 61.6, 14.3; IR (KBr) 1605, 1278, 759, 714 cm⁻¹; HRMS (ESI) calcd for C₁₄H₁₃N₂O₂ (M+H) 241.0972, found 241.0968.



Pyrido[1,2-*b***]indazole-9-carbonitrile (8h**): yield 38 mg (66%); yellowish green solid; mp 65 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.83 (dd, *J* = 7.2, 0.9 Hz, 1 H), 8.51 (dd, *J* = 1.9, 0.9 Hz, 1 H), 8.14 (dt, *J* =

8.3, 1.0 Hz, 1 H), 7.95 (d, J = 8.7 Hz, 1 H), 7.68 (ddd, J = 8.6, 6.8, 1.1 Hz, 1 H), 7.41 (ddd, J = 8.2, 6.8, 0.8 Hz, 1 H), 7.33 (dd, J = 7.2, 1.9 Hz, 1 H); ¹³C NMR(100MHz, CDCl₃) δ 150.2, 133.9, 129.5, 128.3, 123.4, 122.5, 119.5, 117.6, 116.7, 116.4, 116.3, 103.9; IR (KBr) 2225, 1523, 1451, 1361, 1284, 803, 753, 728, 718 cm⁻¹; HRMS (ESI) calcd for C₁₂H₈N₃ (M+H) 194.0713, found 194.0709.



N,*N*-Dimethylpyrido[1,2-*b*]indazol-9-amine (8i): yield 25 mg (40%); yellowish green solid; mp 170-171 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 7.7 Hz, 1 H), 7.94 (d, *J* = 8.2 Hz, 1 H), 7.65 (d, *J* = 8.6 Hz, 1 H), 7.54-7.42 (m, 1 H), 7.03 (t, *J* = 7.4 Hz, 1 H), 6.98 (d, *J* = 2.5 Hz, 1 H), 6.73 (dd, *J* = 7.7, 2.8 Hz, 1 H), 3.09 (s, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 146.5, 137.3, 128.7, 128.2, 120.3, 117.5, 114.3, 114.0, 105.9, 95.0, 40.3; HRMS (ESI) calcd for C₁₃H₁₄N₃ (M+H) 212.1182, found 212.1176.



8,10-Dimethylpyrido[1,2-*b*]indazole (8j): yield 43 mg (73%); slightly yellow solid; mp 116 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.47 (s, 1 H), 8.12 (d, *J* = 8.3 Hz, 1 H), 7.83 (d, *J* = 8.6 Hz, 1 H), 7.59-7.49 (m, 1 H), 7.25-7.17 (m, 1 H), 6.97 (s, 1 H), 2.82 (s, 3 H), 2.43 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 149.4, 133.1, 129.7, 127.4, 126.1, 125.4, 125.3, 124.0, 121.30, 119.4, 115.3, 19.1, 18.4; HRMS (ESI) calcd for C₁₃H₁₃N₂ (M+H) 197.1073, found 197.1069.



7,9-Dimethylpyrido[1,2-*b***]indazole (8k**): yield 32 mg (54%); ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 8.2 Hz, 1 H), 7.86 (d, *J* = 8.7 Hz, 1 H), 7.79 (s, 1 H), 7.57-7.50 (m, 1 H), 7.20-7.14 (m, 1 H), 6.89 (s, 1 H), 2.89 (s, 3 H), 2.50 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.7, 136.8, 135.8, 133.0, 128.2, 120.0, 118.9, 118.1, 115.4, 115.0, 114.5, 21.1, 18.4; HRMS (ESI) calcd for C₁₃H₁₃N₂ (M+H) 197.1073, found 197.1073.



7,8,10-Trimethylpyrido[**1,2-***b***]indazole (8I**): yield 47 mg (75%); ¹H NMR (300 MHz, CDCl₃) δ 8.17 (dt, *J* = 8.3, 1.0 Hz, 1 H), 7.91 (dt, *J* = 8.7, 0.9 Hz, 1 H), 7.54 (ddd, *J* = 8.6, 5.6, 1.1 Hz, 1 H), 7.20 (ddd, *J* = 8.2, 6.8, 0.9 Hz, 1 H), 7.02 (s, 1 H), 2.89 (s, 3 H), 2.85 (s, 3 H), 2.49 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.2, 133.6, 132.5, 127.3, 126.6, 126.0, 123.0, 121.4, 119.1, 116.4, 115.4, 18.9, 18.4, 14.5; HRMS (ESI) calcd for C₁₄H₁₅N₂ (M+H) 211.1230, found 211.1230.

8-Bromopyrido[1,2-*b*]indazole (8m): yield 31 mg (29%); off-white solid; mp 103 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.93 (s, 1 H), 8.05 (d, *J* = 8.3 Hz, 1 H), 8.00 (d, *J* = 9.1 Hz, 1H), 7.85 (d, *J* = 8.7 Hz, 1 H), 7.63-7.56 (m, 1 H), 7.44 (dd, *J* = 9.1, 1.6 Hz, 1 H), 7.30-7.25 (m, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 149.7, 133.9, 128.7, 128.2, 125.1, 120.6, 119.5, 118.1, 115.9, 115.2, 110.9; HRMS (ESI) calcd for C₁₁H₈BrN₂ (M+H) 246.9865, found 246.9861.



10-Bromopyrido[1,2-*b***]indazole (8m')**: yield 49 mg (62%); off-white solid; mp 141 °C; ¹H NMR (300 MHz, CDCL₃) δ 8.78 (dd, *J* = 6.9, 0.8 Hz, 1 H), 8.63 (dt, *J* = 8.5, 1.0 Hz, 1 H), 7.87 (d, *J* = 8.7 Hz, 1 H), 7.61 (ddd, *J* = 8.7, 6.8, 1.1 Hz, 1 H), 7.55 (dd, *J* = 7.5, 0.7 Hz, 1 H), 7.31 (ddd, *J* = 8.4, 6.8, 0.9 Hz, 1 H), 7.05 (t, *J* = 7.2 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.9, 133.2, 128.7, 126.9, 125.3, 122.1, 120.4, 116.0, 115.7, 113.8; HRMS (ESI) calcd for C₁₁H₈BrN₂ (M+H) 246.9865, found 246.9868.



8-Fluoropyrido[1,2-*b***]indazole (8n**): yield 13 mg (24%); white solid; mp 91-92 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.71 (dd, *J* = 4.3, 2.0 Hz, 1 H), 8.14-8.04 (m, 2 H), 7.85 (d, *J* = 8.7 Hz, 1 H), 7.61-7.54 (m, 1 H), 7.30-7.24 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.5 (¹*J*_{CF} = 241.3 Hz), 150.1 (⁴*J*_{CF} = 2.1 Hz), 132.9, 128.1, 120.5, 119.3, 117.9 (³*J*_{CF} = 9.4 Hz), 115.8, 115.6, 115.5 (²*J*_{CF} = 26.3 Hz), 113.1 (²*J*_{CF} = 24.3 Hz); HRMS (ESI) calcd for C₁₁H₈FN₂ (M+H) 187.0666, found 187.0664.



10-Fluoropyrido[**1**,**2**-*b*]**indazole** (**8n**'): yield 25 mg (45%); white solid; mp 95-96 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.63 (d, *J* = 6.7 Hz, 1 H), 8.22 (d, *J* = 8.3 Hz, 1 H), 7.87 (d, *J* = 8.7 Hz, 1 H), 7.65-7.55 (m, 1 H), 7.33-7.28 (m, 1H), 7.18-7.01 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.7 (¹*J*_{CF} = 251.8 Hz), 149.3, 128.6, 127.2 (²*J*_{CF} = 34.0 Hz), 124.2 (⁴*J*_{CF} = 3.9 Hz), 121.3 (⁴*J*_{CF} = 3.4 Hz), 120.9, 115.6, 115.1 (³*J*_{CF} = 7.8 Hz), 113.8 (³*J*_{CF} = 4.5 Hz), 105.9 (²*J*_{CF} = 17.6 Hz); HRMS (ESI) calcd for C₁₁H₈FN₂ (M+H) 187.0660, found 187.0664.



Methyl pyrido[1,2-*b*]indazole-8-carboxylate (8o): yield 36 mg (52%); yellow solid; mp 172 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.46 (s, 1 H), 8.12 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 9.0 Hz, 1 H), 8.07 (d, *J* = 8.3 Hz, 1 H), 7.89 (d, *J* = 8.3 Hz, 1 H), 8.07 (d, J = 8.3 Hz, 1 H), 8.07

10.3 Hz, 1 H), 7.86 (d, J = 8.9 Hz, 1 H), 7.60 (t, J = 7.4 Hz, 1 H), 7.28-7.24 (m, 1 H), 4.01 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 151.2, 136.5, 131.2, 129.4, 121.4, 120.8, 120.1, 119.7, 117.3, 116.0, 115.0, 52.7; HRMS (ESI) calcd for C₁₃H₁₁N₂O₂ (M+H) 227.0815, found 227.0813.



Methyl pyrido[1,2-*b*]indazole-10-carboxylate (8o'): yield 33 mg (47%); yellow solid; mp 128 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.94 (d, *J* = 6.8 Hz, 1 H), 8.79 (d, *J* = 8.6 Hz, 1 H), 8.04 (d, *J* = 7.2 Hz, 1 H), 7.85 (d, *J* = 8.7 Hz, 1 H), 7.59 (t, *J* = 7.3 Hz, 1 H), 7.28-7.24 (m, 1 H), 7.20 (t, *J* = 7.1 Hz, 1 H), 4.08 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 150.7, 133.2, 131.7, 129.0, 126.4, 124.5, 123.6, 120.5, 115.6, 114.7, 114.5, 52.7; IR (KBr) 1720, 1647, 1302, 1089, 740 cm⁻¹; HRMS (ESI) calcd for C₁₃H₁₁N₂O₂ (M+H) 227.0815, found 227.0811



10-Methylpyrido[1,2-*b*]indazole (8p) and 8-methylpyrido[1,2-*b*]indazole (8p'): yield 64 mg (88% combined); yellow solid; major isomer (8p'): ¹H NMR (400 MHz, CDCl₃) δ 8.69 (d, *J* = 6.3 Hz, 1 H), 8.18 (d, *J* = 8.4 Hz, 1 H), 7.86 (d, *J* = 8.6 Hz, 1 H), 7.57 (t, *J* = 7.7 Hz, 1 H), 7.54 (t, *J* = 7.7 Hz, 1 H), 7.17-7.07 (m, 2 H), 2.90 (s, 3 H); minor isomer (8p): ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1 H), 8.05 (d, *J* = 8.2 Hz, 1 H), 8.01 (d, *J* = 8.8 Hz, 1 H), 7.82 (d, *J* = 8.6 Hz, 1 H), 7.25-7.18 (m, 3 H), 2.49 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 130.7, 128.0, 127.8, 126.6, 126.2, 125.7, 124.9, 122.5, 121.6, 119.7, 119.5, 119.5, 117.1, 116, 115.8, 115.4, 115.3, 115.1, 19.3, 18.6; HRMS (ESI) calcd for C₁₂H₁₁N₂ (M+H) 183.0917, found 183.0915.



10-bromo-8-methoxypyrido[**1**,**2**-*b*]**indazole** (**8r**'): yield 34%, beige solid, mp 174-175 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 1.2 Hz, 1 H), 8.24 (d, *J* = 8.3 Hz, 1 H), 7.82 (d, *J* = 8.7 Hz, 1 H), 7.58-7.52 (m, 1 H), 7.28-7.24 (m, 1 H) 6.78 (d, *J* = 1.1 Hz, 1 H), 4.13 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 153.2, 149.1, 128.1, 127.0, 121.7, 121.5, 120.8, 115.43, 115.35, 110.6, 104.4, 56.3; HRMS (ESI) calcd for C₁₂H₁₀BrN₂O (M+H) 276.9971, found 276.9970.



Indazolo[2,3-*a*]quinoline (12a): yield 60 mg (92%); beige solid; mp 98 °C (lit¹⁰ 107-109 °C); ¹H NMR (300 MHz, CDCl₃) δ 8.95 (d, *J* = 8.5 Hz, 1 H), 8.09 (d, *J* = 8.3 Hz, 1 H), 7.99 (dd, *J* = 8.9, 4.8 Hz, 2 H), 7.92 (d, *J* = 8.0 Hz, 1 H), 7.84-7.76 (m, 1 H), 7.68-7.63 (m, 1 H), 7.64-7.53 (m, 2 H), 7.30-7.24 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.1, 134.0, 132.23, 129.3, 128.3, 127.9, 125.9, 125.1, 123.0, 120.6, 119.6, 117.0, 116.6, 116.5, 115.4; HRMS (ESI) calcd for C₁₅H₁₁N₂ (M+H) 219.0917, found 219.0913.



Indazolo[3,2-*a***]isoquinoline** (14*a*): yield 57 mg (87%); light-brown solid; mp 90-92 °C (lit¹⁰ 90-91 °C); ¹H NMR (300 MHz, CDCL₃) δ 8.67 (d, J = 8.2 Hz, 1 H), 8.59 (d, J = 7.4 Hz, 1 H), 8.45 (d, J = 8.5 Hz, 1 H), 7.95 (d, J = 8.7 Hz, 1 H), 7.87 (d, J = 7.9 Hz, 1 H), 7.81-7.71 (m, 1 H), 7.66-7.59 (m, 1 H), 7.56 (dd, J = 4.9, 3.8 Hz, 1 H), 7.40 (d, J = 7.4 Hz, 1 H), 7.35 (ddd, J = 8.4, 6.7, 0.9 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 149.2, 130.5, 128.4, 128.2, 127.5, 127.4, 127.2, 126.4, 126.1, 122.9, 121.3, 121.1, 116.9, 116.4, 116.2; HRMS (ESI) calcd for C₁₅H₁₁N₂ (M+H) 219.0917, found 219.0912.



3-Bromo-5-tosyl-5*H***-pyrido[3,2-***b***]indole (15a)**: yield 63 mg (52%); light-brown solid; mp 231-232 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.76 (d, *J* = 2.0 Hz, 1 H), 8.67 (d, *J* = 2.0 Hz, 1 H), 8.30 (d, *J* = 8.5 Hz, 1 H), 8.18 (d, *J* = 7.2 Hz, 1 H), 7.71 (d, *J* = 8.4 Hz, 2 H), 7.63 (ddd, *J* = 8.5, 7.3, 1.3 Hz, 1 H), 7.45 (td, *J* = 7.5, 0.8 Hz, 1 H), 7.17 (d, *J* = 8.0 Hz, 2 H), 2.32 (d, *J* = 8.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 146.9, 145.7, 143.2, 139.2, 134.3, 132.7, 130.0, 129.7, 126.54, 124.9, 124.74, 124.72, 120.8, 118.0, 114.8, 21.6; HRMS (ESI) calcd for C₁₈H₁₄BrN₂O₂S (M+H) 400.9954, found 400.99529.



3-Bromo-5-tosyl-5*H***-pyrido[3,2-***b***]indole (15b)**: yield 43 mg (41%); light-brown solid; mp 167 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.36 (d, *J* = 2.2 Hz, 1 H), 8.27 (d, *J* = 8.4 Hz, 1 H), 8.12 (d, *J* = 2.3 Hz, 1 H), 8.10 (d, *J* = 7.8 Hz, 1 H), 7.67 (d, *J* = 8.2 Hz, 2 H), 7.50 (t, *J* = 7.7 Hz, 1 H), 7.40 (t, *J* = 7.5 Hz, 1 H), 7.12 (d, *J* = 8.1 Hz, 2 H), 4.00 (s, 3 H), 2.27 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.2, 145.4, 139.0, 138.1, 135.8, 134.6, 133.3, 129.8, 127.9, 126.5, 125.8, 124.5, 119.9, 114.9, 106.7, 56.2, 21.5; HRMS (ESI) calcd for C₁₉H₁₇N₂O₃S (M+H) 353.0954, found 353.0952.



3-Methoxy-5-(2-nitrophenylsulfonyl)-5*H***-pyrido[3,2-***b***]indole (15c): yield 25 mg (22%); yellow solid, mp 224 °C; ¹H NMR (300 MHz, CDCl₃) \delta 8.43 (d,** *J* **= 2.5 Hz, 1 H), 8.22-8.17 (m, 1 H), 8.08-8.03 (m, 1 H), 7.93 (d,** *J* **= 2.5 Hz, 1 H), 7.75–7.64 (m, 2 H), 7.52–7.44 (m, 4 H), 3.98 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) \delta 155.3, 148.0, 138.7, 137.1, 137.0, 134.9, 133.5, 132.3, 131.8, 128.8, 128.1, 125.5, 125.1, 124.9, 120.2, 114.5, 106.4, 56.1; HRMS (ESI) calcd for C₁₈H₁₄N₃O₅S (M+H) 384.0649, found 384.0649.**

Indazolo[3,2-a]isoquinolines:

General procedure for AgOTf-catalyzed cyclization/cycloaddition: to an oven-dried 10 mL round-bottom flask equipped with a stir bar was added 0.3 mmol of

N'-(2-alkynylbenzylidene)tosylhydrazides. CH_3CN (4 mL) was added, followed by 0.03 mmol of AgOTf (10 mol %). The reaction mixture was stirred at 80 °C for 6 h. After being cooled to ambient temperature, 0.36 mmol of aryne precursor (1.2 equiv) was added followed by 0.9 mmol of CsF (3 equiv). The reaction mixture was again stirred at 80 °C for 12 h and cooled to room temperature. It was poured into brine and extracted three times with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the indazolo[3,2-*a*]isoquinolines.



6-*p*-Tolylindazolo[3,2-*a*]isoquinoline (14b): yield 87%; yellow solid, mp 178-179 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.75 (d, *J* = 8.3 Hz, 1 H), 8.52 (d, *J* = 8.5 Hz, 1 H), 7.97 (dt, *J* = 8.7, 0.9 Hz, 1 H), 7.94-7.87 (m, 3 H), 7.76 (ddd, *J* = 8.3, 7.2, 1.3 Hz, 1 H), 7.67-7.60 (m, 1 H), 7.54 (ddd, *J* = 8.7, 6.7, 1.0 Hz, 1 H), 7.44 (s, 1 H), 7.42-7.37 (m, 2 H), 7.37-7.32 (m, 1 H), 2.48 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 148.8, 139.5, 138.5, 131.3, 131.1, 129.5, 129.1, 128.6, 128.0, 127.5, 127.1, 127.0, 125.5, 122.6, 121.3, 121.1, 117.7, 116.7, 116.4, 21.5; IR (KBr) 1619, 1511, 1363, 1233, 809, 752, 724 cm⁻¹; HRMS (ESI) calcd for C₂₂H₁₇N₂ (M+H) 309.1386, found 309.1380.



3-Methyl-6-phenylindazolo[3,2-a]isoquinoline (**14c**): yield 83%; glassy yellow solid, mp 171-172 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.63 (d, *J* = 8.3, 1 H), 8.49 (d, *J* = 8.5 Hz, 1 H), 8.03-7.99 (m, 2 H), 7.95 (d, *J* = 8.7 Hz, 1 H), 7.68 (s, 1 H), 7.64-7.49 (m, 5 H), 7.38 (s, 1 H), 7.37-7.29 (m, 1 H), 2.58 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 148.8, 138.3, 137.2, 134.1, 131.6, 129.8, 129.7, 129.4, 128.8, 128.4, 127.14, 127.05, 123.5, 122.5, 121.1, 121.0, 117.5, 116.6, 116.4, 21.6; IR (KBr) 1610, 1526, 1486, 1355, 1233, 801, 768, 735, 691 cm⁻¹; HRMS (ESI) calcd for C₂₂H₁₇N₂ (M+H) 309.1386, found 309.1384.



3-Fluoro-6-phenylindazolo[3,2-*a***]isoquinoline (14d)**: yield 82%; glassy yellow solid, mp 167-168 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.72 (dd, *J* = 8.9, 5.3 Hz, 1 H), 8.44 (d, *J* = 8.5 Hz, 1 H), 8.03-7.98 (m, 2 H), 7.96 (dt, *J* = 8.7, 0.8 Hz, 1 H), 7.66-7.46 (m, 6 H), 7.39 (s, 1 H), 7.35 (ddd, *J* = 8.4, 6.7, 0.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 161.3 (¹*J*_{CF} = 248.4 Hz), 148.9, 139.4, 133.6, 131.2, 130.2 (³*J*_{CF} = 9.1 Hz), 129.74, 129.66, 128.5, 127.3, 124.8 (³*J*_{CF} = 8.8 Hz), 122.4 (⁴*J*_{CF} = 1.9 Hz), 121.5, 120.8, 117.7, 117.1 (²*J*_{CF} = 24.0 Hz), 116.2, 115.9 (⁴*J*_{CF} = 3.8 Hz), 112.2 (²*J*_{CF} = 21.7 Hz); IR (KBr) 1615, 1561, 1486, 1234, 1226, 879, 760, 732, 690 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₄FN₂ (M+H) 313.1136, found Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012

313.1133.



2-Methoxy-6-phenylindazolo[3,2-*a***]isoquinoline** (**14e**): yield 88%; glassy yellow solid, mp 100-101 $^{\circ}$ C; ¹H NMR (300 MHz, CDCl₃) δ 8.45 (d, *J* = 8.5 Hz, 1 H), 8.08 (d, *J* = 2.4 Hz, 1 H), 8.05-7.92 (m, 3 H), 7.82 (d, *J* = 8.8 Hz, 1 H), 7.63-7.48 (m, 4 H), 7.41 (s, 1 H), 7.35 (ddd, *J* = 8.3, 6.8, 0.7 Hz, 1 H), 7.25 (dd, *J* = 8.7, 2.5 Hz, 1 H), 4.07 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 148.7, 136.2, 134.1, 130.9, 129.6, 129.2, 129.1, 128.4, 126.9, 126.8, 122.9, 121.2, 120.8, 117.6, 117.2, 116.7, 116.6, 103.8, 55.6; IR (KBr) 1620, 1498, 1358, 1267, 1031, 864, 748, 696 cm⁻¹; HRMS (ESI) calcd for C₂₂H₁₇N₂O (M+H) 325.1335, found 325.1330.



2-Chloro-6-phenylindazolo[3,2-*a***]isoquinoline (14f**): yield 86%; glassy yellow solid, mp 202-203 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, *J* = 1.9 Hz, 1 H), 8.46 (d, *J* = 8.5 Hz, 1 H), 8.01-7.96 (m, 3 H), 7.83 (d, *J* = 8.5 Hz, 1 H), 7.63-7.52 (m, 5 H), 7.41 (s, 1 H); 7.39 (ddd, *J* = 8.3, 6.7, 0.9 Hz, 1 H); ¹³C NMR (100 MHz, THF-*d*₈) δ 149.8, 139.7, 134.9, 130.80, 130.78, 130.7, 130.3, 130.1, 128.8, 128.3, 128.0 (overlapped signal), 127.4, 122.7, 122.5, 121.7, 118.4, 117.6, 116.8; IR (KBr) 1619, 1482, 1359, 1235, 860, 735, 691 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₄CIN₂ (M+H) 329.0840, found 329.0836.



6-Phenylindazolo[3,2-*a***]isoquinoline (14g)**: yield 85%; yellow solid, mp 134-135 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 8.2 Hz, 1 H), 8.50 (d, *J* = 8.5 Hz, 1 H), 8.05-8.00 (m, 2 H), 7.98 (d, *J* = 8.7 Hz, 1 H), 7.88 (d, *J* = 7.9 Hz, 1 H), 7.76-7.73 (m, 1 H), 7.64-7.51 (m, 5 H), 7.44 (s, 1 H), 7.38-7.34 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃), δ 148.8, 138.4, 134.0, 131.4, 129.7, 129.5, 128.5, 128.4, 128.1, 127.6, 127.13, 127.11, 125.6, 122.6, 121.4, 121.1, 117.7, 116.8, 116.7; IR (KBr) 1618, 1525, 1484, 1233, 752, 735, 685 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₅N₂ (M+H) 295.1230, found 295.1226.



6-(3-Chlorophenyl)indazolo[3,2-a]isoquinoline (14h): yield 81%; yellow solid, mp 208-209 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.76 (d, J = 8.2 Hz, 1 H), 8.52 (d, J = 8.5 Hz, 1 H), 8.02-8.00 (m, 1 H), 7.99-7.90 (m, 3 H), 7.80 (ddd, J = 8.3, 7.2, 1.3 Hz, 1 H), 7.69-7.62 (m, 1 H), 7.59-7.55 (m, 1 H), 7.53-7.51 (m, 2 H), 7.47 (s, 1 H), 7.38-7.35 (m, 1 H); ¹³C NMR (100 MHz, THF- d_8) δ 149.8, 137.7, 137.1, 134.6, 132.0, 130.7, 130.4, 129.9, 129.4 (overlapped signal), 129.2, 128.8, 128.0, 127.9, 126.7,

123.5, 122.2, 122.0, 118.3, 118.0, 117.5; IR (KBr) 1619, 1595, 1524, 1481, 1365, 1315, 1236, 870, 776, 747, 730, 695 cm⁻¹; HRMS (ESI) calcd for $C_{21}H_{14}CIN_2$ (M+H) 329.0840, found 329.0839.



6-(3-Methoxyphenyl)indazolo[3,2-*a***]isoquinoline** (**14i**): yield 81%; yellow solid, mp 133-134 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 8.2 Hz, 1 H), 8.49 (d, *J* = 8.5 Hz, 1 H), 7.99 (d, *J* = 8.7 Hz, 1 H), 7.87 (d, *J* = 7.9 Hz, 1 H), 7.75-7.71 (m, 1 H), 7.63-7.48 (m, 5 H), 7.44 (s, 1 H), 7.39-7.32 (m, 1 H), 7.12-7.09 (m, 1 H), 3.91 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 148.8, 138.1, 135.1, 131.4, 129.5, 128.4, 128.1, 127.6, 127.1, 127.0, 125.6, 122.6, 122.1, 121.4, 121.0, 117.7, 116.8, 116.6, 115.3, 115.2, 55.4; IR (KBr) 1621, 1597, 1471,1359, 1259, 1047, 782, 749, 736, 698 cm⁻¹; HRMS (ESI) calcd for C₂₂H₁₇N₂O (M+H) 325.1335, found 325.1329.



6-(Thiophen-3-yl)indazolo[3,2-*a***]isoquinoline (14j)**: yield 89%; yellow solid, mp 154-155 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.75 (d, *J* = 8.2 Hz, 1 H), 8.61-8.59 (m, 1 H), 8.54-8.51 (m, 1 H), 8.02 (dt, *J* = 8.7, 0.9 Hz, 1 H), 7.95-7.88 (m, 2 H), 7.76 (ddd, *J* = 8.3, 7.2, 1.3 Hz, 1 H), 7.67 (s, 1 H), 7.66-7,54 (m, 2 H), 7.54-7.51(m, 1 H), 7.37 (ddd, *J* = 8.4, 6.7, 0.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 148.8, 133.7, 133.4, 131.6, 128.3, 128.2, 128.0, 127.5, 127.4, 127.2, 127.1, 125.3, 125.2, 122.5, 121.4, 121.1, 117.5, 116.5, 115.5; IR (KBr) 1600, 1520, 1348, 1296, 1200, 795, 735, 693 cm⁻¹; HRMS (ESI) calcd for C₁₉H₁₃N₂S (M+H) 301.1794, found 301.1791.



6-Pentylindazolo[3,2-*a***]isoquinoline (14I)**: yield 76%; yellow solid, mp 92-93 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.70 (d, *J* = 8.1 Hz, 1 H), 8.49 (d, *J* = 8.5 Hz, 1 H), 8.02 (d, *J* = 8.7 Hz, 1 H), 7.85 (d, *J* = 7.9 Hz, 1 H), 7.76-7.66 (m, 1 H), 7.65-7.51 (m, 2 H), 7.34 (ddd, *J* = 8.3, 6.7, 0.8 Hz, 1 H), 7.27 (s, 1 H), 3.40 (t, *J* = 7.5 Hz, 2 H), 2.07-1.97 (m, 2 H), 1.59-1.39 (m, 4 H), 0.96 (t, *J* = 7.1 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 148.8, 139.6, 130.9, 128.4, 127.3, 127.1, 126.9 (overlapped signal), 125.0, 122.6, 121.3, 121.1, 117.2, 116.8, 113.5, 31.6, 31.2, 26.3, 22.6, 14.0; IR (KBr) 2952, 2930, 1620, 1524, 1366, 1351, 1229, 744 cm⁻¹; HRMS (ESI) calcd for C₂₀H₂₁N₂ (M+H) 289.1699, found 289.1696.



6-((Tetrahydro-2H-pyran-2-yloxy)methyl)indazolo[3,2-a]isoquinoline (14m): yield 60%; yellow

solid, mp 88-89 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.61 (d, *J* = 8.1 Hz, 1 H), 8.42 (d, *J* = 8.5 Hz, 1 H), 7.99 (d, *J* = 8.7 Hz, 1 H), 7.80 (d, *J* = 7.9 Hz, 1 H), 7.72-7.61 (m, 1 H), 7.58-7.53 (m, 2 H), 7.34 (s, 1 H), 7.31 (d, *J* = 7.5 Hz, 1 H), 4.70-4.68 (m, 1 H), 4.36 and 4.15 (t of ABq, ³*J* = 6.4 Hz, *J*_{AB} = 9.9 Hz, 2 H), 3.87-3.80 (m, 1 H, left part of an m of ABq), 3.69 (t, *J* = 6.4 Hz, 2 H), 3.52-3.45 (m, 1 H, right part of an m of ABq), 1.84-1.48 (m, 6 H); ¹³C NMR (75 MHz, CDCl₃), δ 148.6, 136.3, 130.8, 128.3, 127.5, 127.1, 127.0, 126.9, 125.1, 122.5, 121.2, 121.1, 117.2, 116.8, 115.0, 98.9, 64.2, 62.3, 32.0, 30.6, 25.4, 19.5; IR (KBr) 2954, 2921, 1622, 1525, 1236, 1136, 1120, 1032, 979, 752 cm⁻¹; HRMS (ESI) calcd for C₂₂H₂₃N₂O₂ (M+H) 347.1754, found 347.1752.



Indazolo[3,2-a]isoquinoline (14a) from 17m: here this compound was obtained in a modified procedure. Thus, the first step was carried out using 30 mol % of AgOTf for 5 d, and the second step was carried out with additional 0.4 mL of MeOH and 4.0 equiv. of CsF. Yield 40%; light brown solid, mp 88-89 °C (lit¹⁰ 90-91 °C); spectroscopic data match those for **14a**.

General procedure for iodocyclization/cycloaddition: to an oven-dried 10 mL round-bottom flask equipped with a stir bar was added 0.3 mmol of *N*'-(2-alkynylbenzylidene)tosylhydrazides. CH₃CN (4 mL) was added, followed by 0.6 mmol of I₂ (2 equiv). The reaction mixture was stirred at 80 °C for 6 h. After being cooled to ambient temperature, 0.36 mmol of aryne precursor (1.2 equiv) was added followed by 0.9 mmol of CsF (3 equiv). The reaction mixture was again stirred at 80 °C for 12 h and cooled to room temperature. It was poured into sat. aq. Na₂S₂O₃ and extracted three times with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the product **14g'**.



5-Iodo-6-phenylindazolo[3,2-a]isoquinoline (**14g**'): yield 45%; slightly yellow solid, mp 196-197 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.72 (dd, *J* = 8.2, 0.7 Hz, 1 H), 8.48 (d, *J* = 8.6 Hz, 1 H), 8.35 (dd, *J* = 8.3, 0.8 Hz, 1 H), 7.88 (dt, *J* = 8.8, 0.8 Hz, 1 H), 7.82 (ddd, *J* = 8.2, 7.2, 1.2 Hz, 1 H), 7.76-7.60 (m, 4 H), 7.57-7.46 (m, 3 H), 7.35 (ddd, *J* = 8.4, 6.7, 0.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 149.0, 141.3, 138.4, 133.5, 130.7, 130.2, 129.7, 129.6, 129.0, 128.9, 128.1, 127.4, 125.4, 122.9, 122.0, 121.0, 118.0, 116.3, 92.7; IR (KBr) 1624, 1519, 1348, 1246, 752, 694 cm⁻¹; HRMS (ESI) calcd for C₂₁H₁₄IN₂ (M+H) 421.0196, found 421.0197.

General procedure for cycloaddition/AgOTf-catalyzed cyclization: to an oven-dried 25 mL round-bottom equipped flask with а stir bar was added 0.4 mmol of N'-(2-alkynylbenzylidene)tosylhydrazides, followed by 0.48 mmol of the aryne precursor (1.2 equiv). THF (10 mL) was added, followed by 0.1 mmol of TEBAC (0.25 equiv) and 1.2 mmol of CsF (3 equiv). The reaction mixture was stirred at 70 °C for 24 h, cooled to room temperature, poured into brine and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the intermediate.

To an oven-dried 10 mL round-bottom flask equipped with a stir bar was added 0.3 mmol of the intermediate. THF (4 mL) was added, followed by 0.03 mmol of AgOTf (10 mol %). The reaction mixture was stirred at 70 °C for 10 h, cooled to room temperature, poured into brine and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the product **14**.



Intermediate **18**: yield 77%; white solid, mp 120-121 °C; ¹H NMR (400 MHz, CDCl₃) δ 11.9 (brs, 1 H), 7.94 (d, *J* = 8.2 Hz, 1 H), 7.79-7.71 (m, 2 H), 7.47 (dd, *J* = 5.3, 3.6 Hz, 2 H), 7.33 (t, *J* = 7.6 Hz, 1 H), 7.26-7.22 (m, 1 H), 7.15 (t, *J* = 7.7 Hz, 1 H), 6.96-6.87 (m, 4 H), 2.23 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 144.8, 140.6, 137.6, 134.9, 132.4, 130.7, 130.0, 128.3, 127.8, 127.7, 126.0, 122.7, 121.6, 121.4, 120.2, 119. 6, 109.7, 92.7, 88.2, 20.9; HRMS (ESI) calcd for C₂₂H₁₇N₂ (M+H) 309.1386, found 309.1384.

Product **14b** can be obtained in quant yield from the reaction of **18**, with spectroscopic data matching those for **14b** obtained earlier.

References and Notes:

- The petroleum ether we used for column chromatography contains a small quantity of long-chain paraffins. Although we pre-distilled all petroleum ether before use, we still observed small, but visible contamination of the products by such paraffins at ~0.87 ppm and ~1.25 ppm in some of the ¹H NMR spectra. The products obtained are pure otherwise.
- 2. This silica gel exhibits significant difference from the silica gels typically supplied in the US market. The same compound is retarded much less on this silica gel.
- 3. C. Legault, A. B. Charette, J. Org. Chem., 2003, 68, 7119.
- 4. S. L. Jain, V. B. Sharma, B. Sain, Tetrahedron Lett., 2003, 44, 4385.
- 5. J. Zhao, C. Wu, P. Li, W. Ai, H. Chen, C. Wang, R. C. Larock, F. Shi, *J. Org. Chem.*, 2011, **76**, 6837.
- 6. This procedure was taken from Liang's method with modifications, see: Shu, X-Z.; Zhao, S-C.; Ji, K-G.; Zheng, Z-J.; Liu, X-Y.; Liang, Y-M. *Eur. J. Org. Chem.*, 2009, 117.
- 7. X. Creary, W. W. Tam, K. F. Albizati, R. V. J. Stevens, Org. Synth., 1990, 64, 207.
- 8. Anderson, P. N.; Sharp, J. T. J. Chem. Soc., Perkin Trans. 1., 1980, 1331.
- 9. Abrarmnitch, R. A.; Adams, K. A. H. Can. J. Chem., 1961, 39, 2516.
- 10. Yamashita, Y.; Hayashi, T.; Masumura, M. Chem. Lett., 1980, 1133.

Copies of ¹H and ¹³C NMR Spectra:


















































2D NMR Spectra for Compound **8c**: NOESY, showing OMe close to the H at 8.32 ppm.






























































Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is C The Royal Society of Chemistry 2012









2D-NOESY for Compound **8p'**:

















Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is C The Royal Society of Chemistry 2012



2D-HSQC Spectrum for Compound 15b

Note: all carbons are labeled from a to q from higher chemical shift to lower. All hydrogen atoms are labeled according to the carbon atoms they attach to (i.e. Ha means the H attached to Ca).









Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is The Royal Society of Chemistry 2012

Compound 15b:



HMBC correlations (Ts part not shown):

,		
He	Ca, Cd	
Ho	Ca, Cd, Cg	
Hn	Cc, Cl, Ck	
Hi	Cc, Cm	
HI	Ck, Cn	
Hm	Cc, Cd, Ci	

Comparison of calculated vs observed ¹³C NMR chemical shifts:

С	calculated ^a	observed
Ce	127	135
Ca	148	155
Co	100	106
Cg	130	133
Cd	143	138
Ck	127	125
Cc	147	139
Cn	115	114
Ci	129	127
CI	117	124
Cm	124	119
^a ACDLabs, version 6.00		

The other candidate has a 4-bond correlation in HMBC (Hm-Cd). Although less likely, it is not completely impossible and cannot be ruled out.





0



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is C The Royal Society of Chemistry 2012


















































